2025-09-11 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the provided data, formatted for a concise and informative report:

## TransMedics Group Inc. (TMDX) Analysis

TransMedics Group Inc. is a medical technology company pioneering a next-generation organ preservation system for transplant therapy.

### 1. Performance vs. S&P 500 (VOO)

**Key Metrics:**

*   **TMDX Cumulative Return:** 207.27%
*   **VOO Cumulative Return:** 39.61%
*   **Absolute Divergence (Current):** 132.2
*   **Relative Divergence:** 54.0 (Indicates TMDX's outperformance is in the upper half of its historical range relative to VOO).

**Analysis:**

TMDX has significantly outperformed the S&P 500 (VOO). The current divergence suggests substantial outperformance relative to the broader market. A relative divergence of 54.0 indicates that the current level of outperformance is in the upper half of its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
| :----------- | :----- | :----- | :------ | :----- | :----- |
| 2019-2021  | -4.0%  | 63.4%  | -5.0%   | 0.8    | 0.7    |
| 2020-2022  | 140.0% | 68.3%  | 150.0%  | 0.2    | 2.1    |
| 2021-2023  | 95.0%  | 69.4%  | 86.0%   | 0.1    | 2.7    |
| 2022-2024  | 147.0% | 82.8%  | 117.0%  | -0.0   | 2.1    |
| 2023-2025  | 88.0%  | 82.8%  | 43.0%   | 0.0    | 3.7    |

*   **CAGR:** High growth rates in recent periods, showing strong performance.
*   **MDD:** Relatively high Maximum Drawdown values, indicating higher volatility.
*   **Alpha:** Consistently positive Alpha values suggest outperformance compared to its benchmark.
*   **Beta:** Low Beta values suggest the stock is less sensitive to market movements.
*   **Cap(B):** Increasing market capitalization indicates growing investor confidence.

### 2. Recent Stock Price Fluctuations

*   **Current Price:** 108.28
*   **Last Market Data:** Price: 107.79, Previous Close: 108.125, Change: -0.31
*   **5-Day Moving Average:** 105.77
*   **20-Day Moving Average:** 117.31
*   **60-Day Moving Average:** 119.84

**Analysis:**

The stock price is currently below both its 20-day and 60-day moving averages, suggesting a recent downtrend. The 5-day moving average being below the current price could signal a potential short-term bounce. The small change in the Last Market data suggests minimal impact on the current downtrend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3261 (Low Risk)
*   **RSI:** 25.87 (Oversold)
*   **PPO:** -1.26
*   **Hybrid Signal:** cash_60%_Sell 0.1% of holdings (1 shares - Caution - MRI:0.32)
*   **Recent Divergence Change (20-day):** -4.3 (Short-term decrease)
*   **Expected Return:** 84.1% (Over 2 years vs. S&P 500)

**Analysis:**

The RSI indicates the stock is oversold, potentially signaling a buying opportunity. The PPO also points to a negative trend. The MRI suggests a low-risk environment. The hybrid signal suggests caution and a minor selling recommendation based on current indicators. The negative divergence change confirms a recent decline in relative performance. The high expected return suggests long-term optimism.

### 4. Recent News & Analyst Opinions

**Recent News Highlights:**

*   Wall Street is bullish on TransMedics Group (Insider Monkey)
*   TransMedics (TMDX) is a Top Growth Stock for the Long-Term (Zacks)
*   Stifel Initiates TransMedics Group at Neutral With $115 Price Target (MT Newswires)
*   Mixed articles - some positive, some noting recent price declines despite strong earnings.

**Analyst Consensus:**

*   **Consensus:** Buy (1.78)
*   **Target Price:** $138.88 (Average), $170.00 (High), $114.00 (Low)

**Analysis:**

Recent news is generally positive, highlighting growth prospects and analyst bullishness. However, some articles acknowledge recent price declines. Analyst consensus is a "Buy" with a significant upside potential based on the average target price.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
| :--------- | :--- | :----------- |
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:**

TransMedics has consistently exceeded EPS expectations in recent quarters, indicating strong financial performance. The most recent earnings (2025-07-30) were significantly higher than expected.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| :--------- | :------- | :------------ |
| 2025-06-30 | \$0.16B | 61.38%        |
| 2025-03-31 | \$0.14B | 61.47%        |
| 2024-12-31 | \$0.12B | 59.21%        |
| 2024-09-30 | \$0.11B | 55.94%        |
| 2024-06-30 | \$0.11B | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE      |
| :--------- | :------- | :------- |
| 2025-06-30 | \$0.32B | 10.97%   |
| 2025-03-31 | \$0.27B | 9.64%    |
| 2024-12-31 | \$0.23B | 3.00%    |
| 2024-09-30 | \$0.21B | 2.01%    |
| 2024-06-30 | \$0.19B | 6.42%    |

**Analysis:**

Revenue is consistently growing, and profit margins are strong and relatively stable above 55%. Equity is increasing, and ROE has seen significant improvements, indicating efficient capital utilization and strong profitability.

### 7. Overall Assessment

TransMedics Group Inc. (TMDX) demonstrates strong financial performance, significant outperformance relative to the S&P 500, and positive analyst sentiment. While recent price action indicates a short-term downtrend, the stock appears oversold, potentially presenting a buying opportunity. High expected returns and continued revenue and profit growth support a positive long-term outlook.
